This Small-Cap Vaccine Company Offers 14.5% Upisde, Vetr Crowd Says

Shares of small cap clinical-stage vaccine company Novavax, Inc. (NASDAQ: NVAX) have lost more than 14.5 percent since the beginning of the year. However, since mid-May lows, the stock has managed to recuperate more than 65.5 percent of its value.

Nonetheless, the Vetr crowd seems to believe there is still room for upside left, as evidenced by its average price target of $8.66. This implies a potential return of more than 14.6 percent from current valuations.

Related Link: Here's How Crowdsourced Ratings Can Beat The Market

Seeking to better reflect this upside potential, the Vetr community decided upgrade its rating on shares of Novavax on Wednesday, from 4.0 Stars (Buy) to 4.5 Stars (Strong Buy) - out of a possible 5.0 Stars rating.

It should be noted that, in accordance with the new rating, 71 percent of the crowd’s ratings are bullish.